APP-13007 is under clinical development by Formosa Pharmaceuticals and currently in Phase III for Ocular Pain (Eye Pain). According to GlobalData, Phase III drugs for Ocular Pain (Eye Pain) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how APP-13007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

APP-13007 overview

APP-13007 is under development for the treatment of post-operative inflammation and pain of the eye. The drug candidate is administered through ophthalmic route in the form of suspension. It is developed based on the Activus pure nanoparticle technology.

Formosa Pharmaceuticals overview

Formosa Pharmaceuticals is a biopharmaceutical business focused on ophthalmology, cancer, and anti-infectives at both the preclinical and clinical stages. The company is headquartered in Taipei City, Taiwan.

For a complete picture of APP-13007’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.